TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in substance use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain assessed by Wong-Baker FACES
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety assessed by Children Anxiety Meter-State
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fear assessed by Child Fear Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: reduction of dystonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of associated pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severe RDS requiring surfactant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevalence of renal response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Prevalence of patients free of dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Dose-limiting toxicity (DLT) of marizomib as a single agent
Endpoint domain: Adverse events/effects
Primary endpoint: Dose-limiting toxicity (DLT) of marizomib in combination with panobinostat
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose of Marizomib (single agent)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose of Marizomib in combination with panobinostat
Endpoint domain: Adverse events/effects
Primary endpoint: Physique characteristic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standard 9 views of fetal echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prognostic of mortality
Endpoint domain: Mortality/survival
Primary endpoint: Ability to use peripheral vision to recover balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active range of motion at elbow and wrist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score (EVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in the inflammatory profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Wound assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Bleeding Events (Major and Minor)
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma Concentration of Free Dabigatran
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in ADHD-RS Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with adverse events and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Concentration of Carboxyhemoglobin in Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Peak Changes on Items of the Drug Effects Questionnaire (DEQ) - Stimulatory Effects
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Peak Changes on Items of the Drug Effects Questionnaire (DEQ) - Pleasurable Effects
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinician's Eyebrow Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average CMC joint pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Bristol Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in anal incontinence score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nocturnal noninvasive ventilation compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in the number of decayed teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Fractional Iron Absorption (FIA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Liver Vitamin A concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Liver Gene Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver Histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Gene Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: humoral immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cellular immunity response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of HCV positive tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Bolus Pressure and Flow modification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence after incisional hernia repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Chronic pain after incisional hernia repair
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Perioperative complications after incisional hernia repair
Endpoint domain: Adverse events/effects
Primary endpoint: Reoperation after incisional hernia repair
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sensitivity of NIRS Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Specificity of NIRS Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Gestational Age at Birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Variation in inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Degree of Maximum Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-tumour activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of study participants with solicited local and general adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of study participants with unsolicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of study participants with serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Evaluation of the immunogenicity of TV005, assessed by PRNT50 to DENV-1, DENV-2, DENV-3, and DENV-4
Endpoint domain: Physiological/clinical
Primary endpoint: Viral load suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Health Questionnaire 9 (PHQ-9) response
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in RNFL thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to Death or Distant Metastasis
Endpoint domain: Mortality/survival
Primary endpoint: Hematologic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Target Tumor Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: knowledge, attitudes, behaviours, and practices relative to HIV/AIDS and sexually transmitted infections
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: quitting rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Carotid Artery Atherosclerotic Plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: KL Grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC™ Osteoarthritis Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Delis-Kaplan Executive Functioning System (Letter Fluency)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Trail Making Test Part B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of VH
Endpoint domain: Adverse events/effects
Primary endpoint: Total number of TB cases notified
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Grade 3 and 4 Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Jaw movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ramus height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success in the Overall Investigator's Global Assessment of Disease Severity (IGA) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to administer IgG in a single infusion site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mild local adverse drug reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Caregiver use of harsh discipline practices
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parent-Child Interactions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Short-term femoral head penetration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term steady state wear of polyethylene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stability of acetabular & femoral components
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference of the CCI score at day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Full Body Fat Percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Pharyngitis symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MCA flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: cerebral O2 saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in the Mean Value of HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in alcohol and drug use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Peak Oxygen Uptake (VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regional Fat Metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Functional Symmetry Observation Scale (FSOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of words in a grade-level passage read correctly in one minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disruptive Behavior Disorders Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Wechsler Abbreviated Scale of Intelligence
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Recurrence of sustained VT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Chemotherapy complete rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Structured interviews
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall Survival Rate at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Physiologic Signal Detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotion Regulation Skills
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants with hypersensitivity
Endpoint domain: Adverse events/effects
Primary endpoint: Pressure readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PaCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Intra-operative and post operative adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: recurrent cardiovascular events (AMI, stroke)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: lifethreatening arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Expert rating on well-being
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall measurement of pharmacokinetic parameter values of ABT-493 and ABT-530
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall measurement of safety parameters
Endpoint domain: Adverse events/effects
Primary endpoint: Thickness of the masseter and temporalis muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in the biomechanical properties of the masticatory muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prescription efficiency
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of diseased sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pre Dialysis Plasma Oxalate Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in sperm counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Long-Term Renal Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Histomorphometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intelligence quotient (IQ)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Complete virologic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of Staphylococcus Aureus in cutaneous biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Free (unbound) drug concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weekly Binge/Purge Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spirometric measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Forced Oscillation technique measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in blood transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Detection of blaNDM-1 and blaKPC gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change of AUC and Cmax of dolasetron, granisetron and rosiglitazone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fat Oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Satisfied With Pain Treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Muscle mitoquinone mesylate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective symptoms/Mood Effects
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: CNS norepinephrine turnover
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of BOLD-MRI signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Functional connectivity of activated regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a Static Physician Global Assessment (sPGA) (0,1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle strength of the pelvic floor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Most Frequent & Most Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of struts' neointimal coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Patient quality of life measured by EQ-5D-5L score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient quality of life measured by Atrial Fibrillation Effect of Quality of Life score (AFEQT)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient quality of life measured by Perception of Anticoagulant Treatment Questionnaire (PACT-Q)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Participants With Minimal Residual Disease Negative Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fugl-Meyer Upper Extremity (FMUE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Reporting Solicited Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Reporting Unsolicited Non-serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Time to First Clinical Malaria Episode With Significant Parasitemia and Temperature
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Reporting Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Type of Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) and Current NOAC Dose According to Sex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Years Since First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation to Study Visit According to Sex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Type of Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) and NOAC Dose According to Age (Categorical)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Years Since First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation to Study Visit According to Patient's Age (Categorical)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Visual Analog Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects With Target Lesion Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion with failure (clinical or virological)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coverage of recent HIV testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 30-Second Chair Stand Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinalyses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Modified Cantril Ladder
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PedsQL 4.0 Generic Core Scale, Parent Proxy
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and severity of vaccine-related reactogenicity events
Endpoint domain: Adverse events/effects
Primary endpoint: H5 HAI titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Dying or Requiring ICU Admission
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Who are Dependent on High Flow Oxygen Devices or Invasive Mechanical Ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline of retinal vessel density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of retinal perfusion density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of foveal avascular zone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of retinal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of unprotected coital or oral-genital activity
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: changes in frequency of central sleep apnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Patients With at Least 1 Hospital Readmission Within 30 Days After Enrollment
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Patients With at Least 1 Hospital Readmission Within 180 Days After Enrollment
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Clinical features of non-IgE mediated food allergies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants' responses to survey questions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dose-limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: PASI 75 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes